Mineralys Therapeutics, Inc. (MLYS)
Fuera de horario:
Mineralys Therapeutics, Inc.
150 N. Radnor Chester Rd.
Suite F200
Radnor, PA 19087
United States
888 378 6240
https://mineralystx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 28
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D. | Founder & Executive Chairman | 69.33k | N/D | 1977 |
| Mr. Jon Congleton | CEO & Director | 775.77k | N/D | 1963 |
| Mr. Adam Scott Levy | CFO & Secretary | 655.58k | N/D | 1978 |
| Dr. David M. Rodman M.D. | Chief Medical Officer | 726.95k | N/D | 1955 |
| Ms. Cindy Berejikian | Executive Vice President of Operations | N/D | N/D | N/D |
| Ms. Sarah Foster | Vice President of Human Resources | N/D | N/D | N/D |
| Dr. Robert McKean Ph.D. | Senior Vice President of CMC | N/D | N/D | N/D |
| Ms. Danielle Bradbury | Senior Vice President of Quality Assurance | N/D | N/D | N/D |
| Mr. Jeffrey N. Fellows | Senior Vice President of Regulatory Affairs | N/D | N/D | N/D |
| Ms. Jessica Ibbitson | Senior Vice President of Clinical Operations | N/D | N/D | N/D |
Descripción
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Gestión corporativa
La calificación ISS Governance QuickScore de Mineralys Therapeutics, Inc. a partir del 1 de mayo de 2024 es 9. Las puntuaciones principales son Auditoría: 5; Junta: 10; Derechos del accionista: 8; Compensación: 8.
